Sabine Lisicki

Calgary National Bank Challenger Announces World Renowned Players for 2023 Event

Retrieved on: 
Thursday, October 5, 2023
Venus, ATC, Tournament, ATP Finals, Downtown Calgary, Core, Sabine Lisicki, ATP, Former, Urszula, 2022 Australian Open – Women's singles, Running, 2022 Calgary National Bank Challenger, ATP Tour 250, WTA, Challenger, 2009 ATP World Tour, Swedish Open, Radwańska, Online shopping

CALGARY, Alberta, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Today, Calgary National Bank Challenger ("The Challenger" or "The Tournament") Tournament Director and CEO of the OSTEN & VICTOR Tennis Centre (ATC) Danny Da Costa, announced the first three players to compete at this year's Calgary National Bank Challenger.

Key Points: 
  • CALGARY, Alberta, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Today, Calgary National Bank Challenger ("The Challenger" or "The Tournament") Tournament Director and CEO of the OSTEN & VICTOR Tennis Centre (ATC) Danny Da Costa, announced the first three players to compete at this year's Calgary National Bank Challenger.
  • The Challenger is taking place at the OSTEN & VICTOR Alberta Tennis Centre from November 5-12, 2023.
  • Returning to the Calgary National Bank Challenger for the second consecutive year, is former World No.
  • She has defeated several World #1 singles players in her career including: Serena Williams, Venus Williams, Maria Sharapova, Ana Ivanovic and Caroline Wozniacki.

Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors

Retrieved on: 
Monday, July 24, 2023
Inflammation, PDMA, Amgen, BS, Sabine Lisicki, Therapy, State University of New York, Arena Pharmaceuticals, Compensation, State university system, EMA, Economics, Acquisition, Immunology, Regeneron Pharmaceuticals, FDA, Pfizer, Pharmaceutical industry, Pain, Circulatory system

PONTE VEDRA, Fla., July 24, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the appointment of Robert Lisicki to its Board of Directors and Compensation and Nomination/Governance Committees.

Key Points: 
  • PONTE VEDRA, Fla., July 24, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the appointment of Robert Lisicki to its Board of Directors and Compensation and Nomination/Governance Committees.
  • "I look forward to leaning on his executive experience and commercial vision as a member of the Cadrenal board."
  • "I believe Cadrenal Therapeutics is developing a novel and potentially paradigm-changing therapeutic," said Robert Lisicki.
  • Lisicki will occupy a newly created seat on the Cadrenal Board of Directors.